zelboraf
roche registration gmbh - vemurafenib - melanom - antineoplastische mittel - vemurafenib ist in monotherapie zur behandlung von erwachsenen patienten mit braf-v600-mutation-positivem inoperablem oder metastasiertem melanom indiziert.
tremfya
janssen-cilag international nv - guselkumab - psoriasis - immunsuppressiva - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.
bimzelx
ucb pharma s.a. - bimekizumab - psoriasis - immunsuppressiva - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.
idefirix
hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - immunsuppressiva - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.
zytrim 50mg filmtablette
recordati pharma gmbh - azathioprin - filmtablette - azathioprin 50.mg
zytrim 50mg filmtablette
recordati pharma gmbh - azathioprin - filmtablette - azathioprin 50.mg
opdivo 40 mg/4 ml konzentrat zur herstellung einer infusionslösung
bristol-myers squibb sa - nivolumabum - konzentrat zur herstellung einer infusionslösung - nivolumabum 40 mg, natrii citras dihydricus, natrii chloridum, mannitolum, acidum penteticum, polysorbatum 80, acidum hydrochloridum, natrii hydroxidum, aqua ad iniectabile q.s. ad solutionem pro 4 ml corresp. natrium 10 mg. - onkologikum - biotechnologika
opdivo 100 mg/10 ml konzentrat zur herstellung einer infusionslösung
bristol-myers squibb sa - nivolumabum - konzentrat zur herstellung einer infusionslösung - nivolumabum 100 mg, natrii citras dihydricus, natrii chloridum, mannitolum, acidum penteticum, polysorbatum 80, acidum hydrochloridum, natrii hydroxidum, aqua ad iniectabile q.s. ad solutionem pro 10 ml corresp. natrium 25 mg. - onkologikum - biotechnologika
opdivo 240 mg/24 ml konzentrat zur herstellung einer infusionslösung
bristol-myers squibb sa - nivolumabum - konzentrat zur herstellung einer infusionslösung - nivolumabum 240 mg, natrii citras dihydricus, natrii chloridum, mannitolum, acidum penteticum, polysorbatum 80, acidum hydrochloridum, natrii hydroxidum, aqua ad iniectabile q.s. ad solutionem pro 24 ml corresp. natrium 60 mg. - onkologikum - biotechnologika
keytruda 100 mg/4 ml konzentrat zur herstellung einer infusionslösung
msd merck sharp & dohme ag - pembrolizumabum - konzentrat zur herstellung einer infusionslösung - pembrolizumabum 100 mg, histidinum, histidini hydrochloridum monohydricum, polysorbatum 80, saccharum, aqua ad iniectabile q.s. ad solutionem pro 4 ml. - onkologikum - biotechnologika